Fig 1: 13(S)-HODE and (S)-2HB target the IFN-? signaling axis. (A) Immunoblotting of Pirc and WT tissues. Each lane represents an individual tumor or normal tissue. (B) Immunoblotting of HCT116 and MC38 cells 7 d after treatment with 100 µM (S)-2HB, 2.5 µM 13(S)-HODE, or 100 µM (S)-2HB plus 2.5 µM 13(S)-HODE, with 1 mM NaB as a control. (C) B2M and IFNG mRNA expression in HCT116 cells following 7-d treatments as in ‘B’, RT-qPCR data normalized to GAPDH; mean ± SD, n = 3. (D) FACS-based analysis of ß2m cell suface occupancy in MC38 cells 7 d after treatment with test agents as in ‘B’, or with IFN-? (10 ng/mL) for 20 h. (E) Immunoassay-based assessment [17] of ovalbumin (OVA) antagonistic peptide-driven IL-2 secretion from murine OVA-specific B3Z T cell hybridoma co-incubated with MC38-OVA cells [16], treated as in panel ‘C’. Mean ± SD, n = 3. Bars with different superscripts differed significantly based on group comparisons via one-way ANOVA.